NCT05714345Phase 2Terminated

Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

Study sponsor: Allogene Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-02-20Actual
Enrollment · participants2Actual
Source updated2026-03-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview